Adherence and persistence with fluticasone propionate/salmeterol combination therapy - 16/08/11
, Alex Pedan, PhD c, Laleh T. Varasteh, RPh, MSF c
Reprint requests: Bruce G. Bender, PhD, Professor and Head, Pediatric Behavioral Health, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206.Denver, Colo, and Burlington, Mass
Abstract |
Background |
Pharmacy database medication refill studies provide a panoramic view of medication-taking behavior in patients nationally.
Objective |
To investigate fluticasone propionate/salmeterol combination (FSC) adherence, including the factors associated with refill adherence in a large national pharmacy database.
Methods |
Adherence and persistence were documented for 12 months from date of initial FSC prescription in 5504 patients who filled their medication at a nationwide pharmacy chain.
Results |
On average, patients filled enough medication to cover 22.2% of days. More than half the patients filled a 30-day prescription only once over the 1-year interval. Higher adherence levels were associated with being male, being older than 35 years, having a comorbid disorder, a having a copay of $1.01 to $10, previous β2-agonist use, and a prescription for higher-dose FSC.
Conclusion |
This pharmacy database study portrays medication adherence levels to be considerably lower than those reported in most clinical trials, suggests that most adults taking FSC obtain a single fill before abandoning their controller medication, and indicates a need for a reappraisal of current treatment guidelines and educational strategies for both providers and patients.
Clinical implications |
For many patients, filling of a controller medication is markedly discrepant with practice guidelines. Reappraisal of both the guidelines and strategies to implement them is in order.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, chronic obstructive pulmonary disease, adherence, persistence, fluticasone propionate, salmeterol, inhaled corticosteroid
Abbreviations used : FSC, ICS
Plan
| Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest. |
Vol 118 - N° 4
P. 899-904 - octobre 2006 Retour au numéro
Article précédent
- Exposure to Alternaria alternata in US homes is associated with asthma symptoms
- Päivi M. Salo, Samuel J. Arbes, Michelle Sever, Renee Jaramillo, Richard D. Cohn, Stephanie J. London, Darryl C. Zeldin
- Human subjects without peanut allergy demonstrate T cell–dependent, TH2-biased, peanut-specific cytokine and chemokine responses independent of TH1 expression
- Tina B. Thottingal, Bill P. Stefura, F. Estelle R. Simons, Gary A. Bannon, Wesley Burks, Kent T. HayGlass, for the Canadian Institutes of Health Research National Training Program in Allergy and Asthma Research
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?